IceCure Medical (NASDAQ:ICCM) Price Target Raised to $2.50

Key Points

• Investment analysts at HC Wainwright have raised their price target for IceCure Medical from $2.00 to $2.50, indicating a potential upside of 150.00% from the previous closing price.
• IceCure Medical's stock was up 3.7% following the announcement, opening at $1.00 but has a 52-week low of $0.48 and a high of $1.66.
• The company reported earnings of $0.06 per share, surpassing expectations, but had a negative net margin of 317.62% during its last quarterly earnings.

IceCure Medical (NASDAQ:ICCM - Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $2.00 to $2.50 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target would suggest a potential upside of 150.00% from the company's previous close.

ICCM has been the topic of a number of other research reports. Wall Street Zen downgraded IceCure Medical from a "hold" rating to a "sell" rating in a report on Saturday, July 12th. Zacks Research cut shares of IceCure Medical from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. Loop Capital set a $2.77 price objective on shares of IceCure Medical in a research report on Wednesday, August 13th. Brookline Capital Management reaffirmed a "buy" rating on shares of IceCure Medical in a research report on Wednesday, August 13th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of IceCure Medical in a research report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, IceCure Medical currently has a consensus rating of "Moderate Buy" and an average price target of $2.64.

IceCure Medical Stock Up 3.7%

Shares of IceCure Medical stock opened at $1.00 on Tuesday. The company has a quick ratio of 0.88, a current ratio of 1.18 and a debt-to-equity ratio of 0.02. IceCure Medical has a 52-week low of $0.48 and a 52-week high of $1.66. The company has a market capitalization of $68.70 million, a P/E ratio of -6.25 and a beta of 0.31. The company has a 50 day moving average of $0.98 and a 200 day moving average of $1.04.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.12. The business had revenue of $0.66 million during the quarter, compared to analysts' expectations of $0.90 million. IceCure Medical had a negative net margin of 317.62% and a negative return on equity of 136.96%. As a group, research analysts forecast that IceCure Medical will post -0.28 EPS for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.